Case-Based Learning: Unexplained Coagulation Abnormality With Normal Platelet Count

Abstract

An abnormal prothrombin time, activated partial thromboplastin time, or both in a patient with a normal platelet count represents a diagnostic problem involving plasma coagulation factors, natural anticoagulants, medications, inhibitors, liver function, and preanalytical error. Because platelet enumeration does not assess secondary hemostasis, clinically important bleeding or thrombosis may occur despite a normal platelet count. A case-based approach begins with confirmation of the result, characterization of the abnormal pathway, careful medication and transfusion history, and targeted laboratory testing. Isolated prolongation of the activated partial thromboplastin time suggests heparin exposure, lupus anticoagulant, or deficiency or inhibition of factors VIII, IX, XI, or XII, whereas an isolated prolonged prothrombin time raises concern for vitamin K deficiency, warfarin effect, factor VII deficiency, or early liver dysfunction. Simultaneous prolongation of both tests broadens the differential to severe vitamin K deficiency, advanced hepatic disease, disseminated intravascular coagulation, direct anticoagulants, common-pathway factor deficiency, and acquired inhibitors. Mixing studies, thrombin time, anti-Xa assays, fibrinogen measurement, factor assays, and inhibitor testing provide mechanism-based clarification. Management depends on the presence and severity of bleeding, the implicated mechanism, and the urgency of any procedure. This review presents a practical framework for clinicians evaluating unexplained coagulation abnormalities with preserved platelet counts.

Introduction

Coagulation testing is frequently obtained during preoperative assessment, emergency evaluation, investigation of bleeding, or monitoring of anticoagulant therapy. An unexpected abnormality can generate substantial concern, yet the result is not itself a diagnosis. A normal platelet count indicates that platelet number is preserved, but it does not exclude platelet dysfunction, impaired fibrin formation, excessive fibrinolysis, or clinically significant anticoagulant activity. The central clinical task is to determine whether the laboratory finding reflects a true hemostatic defect, an acquired inhibitor, medication effect, or a technical problem.

Case-based reasoning is particularly valuable because the same prolonged test may have very different implications in an asymptomatic patient, a patient with new soft-tissue bleeding, or a patient requiring urgent surgery. Interpretation should integrate bleeding history, thrombosis history, liver and renal function, recent procedures, pregnancy or postpartum status, malignancy, infection, autoimmune disease, nutritional status, and all prescription, nonprescription, and parenteral medications. A structured approach reduces unnecessary plasma transfusion and prevents harmful delays in diagnosing conditions such as acquired hemophilia A.

Epidemiology / Disease Burden

Unexpected prolongation of routine coagulation tests is common in hospitals and outpatient procedural settings. The frequency increases among hospitalized patients because of critical illness, liver dysfunction, nutritional deficiency, antibiotic exposure, heparin contamination, and use of direct oral anticoagulants. Most abnormal results do not represent a single inherited bleeding disorder. Instead, acquired causes and preanalytical factors predominate in adults without a lifelong bleeding history.

The clinical burden is determined less by the numerical prolongation than by its mechanism and the patient context. Some lupus anticoagulants markedly prolong the activated partial thromboplastin time while being associated with thrombosis rather than bleeding. Conversely, a patient with an acquired factor VIII inhibitor may have a modestly abnormal screening test but develop extensive spontaneous ecchymoses, muscle hematomas, gastrointestinal bleeding, or postpartum hemorrhage. Misclassification can lead to inappropriate vitamin K, plasma, anticoagulant reversal, or invasive procedures without adequate hemostatic planning.

Pathophysiology

Prothrombin time primarily assesses the tissue-factor and common pathways, with particular sensitivity to factor VII and, at greater severity, factors X, V, II, and fibrinogen. The activated partial thromboplastin time assesses contact, intrinsic, and common pathways, including factors XII, XI, IX, VIII, X, V, II, and fibrinogen. These tests are phospholipid-dependent clotting assays and do not directly measure platelet function, endothelial integrity, or in vivo thrombin generation.

An isolated prolonged activated partial thromboplastin time may result from heparin contamination, unfractionated heparin, some direct oral anticoagulants, lupus anticoagulant, or deficiency of factors VIII, IX, XI, or XII. Factor XII deficiency can produce a striking laboratory abnormality without a bleeding phenotype. Factor VIII inhibition, in contrast, usually causes clinically important bleeding. An isolated prolonged prothrombin time is associated with warfarin exposure, vitamin K deficiency, factor VII deficiency, and early hepatic synthetic dysfunction. Prolongation of both assays suggests multiple factor deficiency or inhibition, severe liver disease, disseminated intravascular coagulation, anticoagulant effect, or a common-pathway abnormality.

Mixing studies help distinguish deficiency from inhibition. Correction after mixing patient plasma with normal plasma supports a factor deficiency, whereas failure to correct suggests an inhibitor or anticoagulant. Time-dependent inhibitors may initially show partial correction and become more evident after incubation. Interpretation must account for reagent sensitivity, the ratio of patient to normal plasma, incubation conditions, and concurrent anticoagulants.

Risk Factors

Important risk factors include exposure to unfractionated heparin, low-molecular-weight heparin, warfarin, direct oral anticoagulants, argatroban, or contaminated intravenous lines. Malnutrition, malabsorption, prolonged antibiotic therapy, cholestasis, and inadequate vitamin K intake predispose to vitamin K deficiency. Liver disease, sepsis, shock, trauma, obstetric complications, advanced cancer, and major transfusion can produce complex acquired coagulopathy. Autoimmune disease, hematologic malignancy, solid tumors, pregnancy, and the postpartum period increase the likelihood of an acquired factor inhibitor.

A personal history of excessive bleeding after dental extraction, surgery, trauma, or childbirth suggests an inherited disorder, although mild hemophilia or von Willebrand disease may remain undiagnosed until adulthood. Family history is helpful but not definitive because de novo disease, variable penetrance, and limited family exposure can obscure inherited conditions. Recent hospitalization also raises the possibility of specimen collection from a line containing heparin or incorrect blood-to-citrate volume caused by an underfilled tube.

Clinical Features

The bleeding pattern provides mechanistic clues. Mucocutaneous bleeding, menorrhagia, epistaxis, and immediate bleeding after procedures often point toward platelet dysfunction or von Willebrand disease, although they may coexist with plasma factor abnormalities. Deep muscle hematomas, large ecchymoses, retroperitoneal bleeding, hemarthrosis, and delayed postoperative hemorrhage favor a coagulation factor defect or inhibitor. Absence of bleeding does not guarantee safety, particularly before neuraxial anesthesia, surgery, central nervous system procedures, or organ biopsy.

Thrombosis accompanying an abnormal activated partial thromboplastin time should prompt consideration of lupus anticoagulant, antiphospholipid syndrome, cancer-associated thrombosis, or an anticoagulant medication rather than an assumption of bleeding risk. Patients with liver disease or disseminated intravascular coagulation may have simultaneous bleeding and thrombosis, reflecting disrupted balance across procoagulant, anticoagulant, and fibrinolytic systems.

Diagnosis

First, repeat the complete blood count, prothrombin time, activated partial thromboplastin time, fibrinogen, and liver profile using a properly collected peripheral specimen. Confirm that the citrate tube was adequately filled and that the sample was not drawn proximal to an infusion. Review the international normalized ratio, absolute test values, laboratory reference intervals, and previous results. Document all anticoagulants, last doses, renal function, transfusions, and use of topical or flush heparin.

Testing should then be directed by the pattern. Thrombin time is highly sensitive to heparin and may detect some direct thrombin inhibitors; a reptilase time can help distinguish heparin effect from fibrinogen-related abnormalities. Anti-Xa assays may identify heparin or factor Xa inhibitor activity, but calibration and local laboratory methodology are important. Fibrinogen, D-dimer, and blood-film findings support evaluation for disseminated intravascular coagulation. Factor assays should be interpreted cautiously when lupus anticoagulant or direct oral anticoagulants are present because assay interference can mimic factor deficiency.

When an inhibitor is suspected, factor VIII activity and a Bethesda or Nijmegen-modified Bethesda inhibitor assay are essential. Lupus anticoagulant testing generally uses phospholipid-dependent screening and confirmatory procedures, with consideration of anticoagulant interference. If the initial evaluation is unrevealing, specialized testing for von Willebrand disease, rare factor deficiency, dysfibrinogenemia, or abnormal fibrinolysis may be required in consultation with a coagulation laboratory.

Treatment & Management

Management begins with clinical triage. Life-threatening bleeding requires resuscitation, source control, urgent hematology consultation, and mechanism-directed hemostatic therapy. Anticoagulants should be withheld when clinically appropriate, but reversal must balance bleeding risk against thrombosis risk. Red-cell support, fibrinogen replacement when low, and targeted plasma or factor replacement may be necessary. Empirical plasma should not be used reflexively for every abnormal screening test, particularly when the patient is stable and a specific diagnosis is pending.

Vitamin K deficiency or warfarin effect may be treated with vitamin K, with four-factor prothrombin complex concentrate generally preferred for urgent reversal of serious warfarin-associated bleeding according to local protocols. Heparin-related abnormalities require discontinuation and, in severe bleeding, protamine when appropriate. Direct oral anticoagulant reversal depends on the agent, timing, renal function, bleeding severity, and availability of specific antidotes or nonspecific replacement strategies.

Acquired hemophilia A requires rapid control of bleeding with bypassing agents or recombinant porcine factor VIII in suitable patients, followed by inhibitor eradication using immunosuppression. Corticosteroids, often combined with rituximab or another immunosuppressive agent, are selected according to inhibitor burden, comorbidity, infection risk, and guideline-based risk stratification. Lupus anticoagulant without bleeding generally does not warrant plasma replacement; management focuses on thrombotic risk assessment and treatment of antiphospholipid syndrome when diagnostic criteria are met.

Recent Advances / Emerging Therapies

Modern coagulation laboratories increasingly use calibrated drug-specific anti-Xa assays, dilute thrombin time, ecarin-based assays, and mass-spectrometric methods to identify anticoagulant effects when routine tests are unreliable. Viscoelastic testing can provide rapid information about clot initiation, strength, and fibrinolysis in trauma, surgery, and critical illness, although it complements rather than replaces conventional factor-specific testing.

Specific reversal agents have expanded the therapeutic options for direct oral anticoagulants. Idarucizumab rapidly neutralizes dabigatran, while andexanet alfa can reverse factor Xa inhibitor activity in selected major bleeding situations, subject to availability, cost, thrombotic risk, and institutional protocols. Research continues on safer factor replacement, more selective immune therapies for acquired inhibitors, and laboratory platforms capable of distinguishing drug effect from endogenous coagulation disorders with greater speed and accuracy.

Guideline Recommendations

Guideline-consistent practice emphasizes clinical assessment before laboratory correction, repeat testing when results are unexpected, and specialist consultation for major bleeding, suspected acquired hemophilia, or urgent invasive procedures. Anticoagulant reversal should be reserved for clinically significant bleeding or high-risk urgent intervention rather than an isolated abnormal number. Testing for lupus anticoagulant and factor inhibitors should be interpreted in the context of medication interference and acute illness. Patients with suspected inherited disorders should receive confirmatory evaluation outside the acute bleeding episode whenever feasible.

Before surgery, clinicians should avoid relying on platelet count alone. A normal count does not establish adequate secondary hemostasis, and a prolonged screening test should be explained before proceeding with neuraxial or high-risk procedures. Communication among the treating clinician, anesthesiologist, transfusion service, and hematologist is essential when the diagnosis remains uncertain. Every decision should document bleeding severity, thrombosis risk, the probable mechanism, and the expected benefit and harm of replacement therapy.

Conclusion

Unexplained coagulation abnormalities with a normal platelet count require a structured, mechanism-based evaluation rather than reflexive correction. Confirmation of the result, identification of the affected pathway, medication review, mixing studies, and targeted factor or inhibitor testing usually transform an apparently nonspecific abnormality into a clinically interpretable diagnosis. The most important distinction is between deficiency, anticoagulant effect, and inhibitor, because each demands a different treatment strategy. Careful integration of laboratory findings with bleeding phenotype and thrombotic risk improves diagnostic accuracy, reduces unnecessary transfusion, and enables timely treatment of serious acquired disorders such as acquired hemophilia A.